Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

71.07
-0.7000-0.98%
Volume:296.42K
Turnover:21.06M
Market Cap:7.49B
PE:63.77
High:71.79
Open:71.64
Low:70.03
Close:71.77
Loading ...

Corcept Therapeutics Submits New Drug Application for Relacorilant to FDA for Treatment of Platinum-Resistant Ovarian Cancer

Reuters
·
14 Jul

Piper Sandler Sticks to Its Buy Rating for Corcept Therapeutics (CORT)

TIPRANKS
·
11 Jul

Piper Sandler pharmaceuticals analyst holds analyst/industry conference call

TIPRANKS
·
10 Jul

Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension

TIPRANKS
·
10 Jul

Sean Maduck, President of Corcept Endocrinology, Reports Disposal of Common Shares of Corcept Therapeutics Incorporated

Reuters
·
04 Jul

Corcept Therapeutics (CORT) Receives a Buy from Truist Financial

TIPRANKS
·
26 Jun

BRIEF-Corcept Therapeutics Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1c

Reuters
·
24 Jun

Corcept says Catalyst trial met primary endpoint

TIPRANKS
·
24 Jun

Corcept Therapeutics Unveils Promising CATALYST Trial Results at ADA Scientific Sessions, Highlighting Efficacy of Cortisol Modulator in Treating Hypercortisolism in Type 2 Diabetes Patients

Reuters
·
24 Jun

Top Executive Sells Thousands in Corcept Therapeutics Stock!

TIPRANKS
·
19 Jun

Gary Charles Robb, Chief Business Officer, Reports Disposal of Corcept Therapeutics Common Shares

Reuters
·
19 Jun

Corcept Therapeutics Incorporated Held Annual Stockholders Meeting

Reuters
·
17 Jun

William Guyer, Chief Development Officer, Reports Disposal of Common Shares in Corcept Therapeutics Inc

Reuters
·
13 Jun

Analysts Conflicted on These Healthcare Names: Corcept Therapeutics (CORT), Biogen (BIIB) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
12 Jun

Corcept Therapeutics Says Its ALS Drug Candidate Fails to Meet Primary Goal

MT Newswires Live
·
05 Jun

Joseph Douglas Lyon, Officer, Reports Disposal of Common Shares of Corcept Therapeutics Incorporated

Reuters
·
05 Jun

Buy Rating for Corcept Therapeutics Based on Promising Phase III ROSELLA Study Results

TIPRANKS
·
03 Jun

Promising ROSELLA Study Boosts Buy Rating for Corcept Therapeutics with Relacorilant’s Potential in Ovarian Cancer Treatment

TIPRANKS
·
03 Jun

Corcept Therapeutics Says Relacorilant Met Primary Endpoint in Phase 3 Ovarian Cancer Trial

MT Newswires Live
·
02 Jun

Corcept Therapeutics says Phase 3 ROSELLA trial met primary endpoint

TIPRANKS
·
02 Jun